ID   ANBL-6 BR
AC   CVCL_QZ43
DR   cancercelllines; CVCL_QZ43
DR   Wikidata; Q54749909
RX   PubMed=19344406;
CC   Population: Caucasian.
CC   Characteristics: Produces Ig lambda.
CC   Characteristics: IL6 dependent.
CC   Selected for resistance to: ChEBI; CHEBI_52717; Bortezomib (Velcade).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:12033; TRAF3; Simple; p.Tyr425Thrfs*36 (c.1272delC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5425 ! ANBL-6
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 19-12-24; Version: 10
//
RX   PubMed=19344406; DOI=10.1111/j.1365-2141.2009.07647.x; PMCID=PMC3018832;
RA   Voorhees P.M., Chen Q., Small G.W., Kuhn D.J., Hunsucker S.A.,
RA   Nemeth J.A., Orlowski R.Z.;
RT   "Targeted inhibition of interleukin-6 with CNTO 328 sensitizes
RT   pre-clinical models of multiple myeloma to dexamethasone-mediated cell
RT   death.";
RL   Br. J. Haematol. 145:481-490(2009).
//